



13794 NW 4th Street  
Suite 212  
Sunrise, FL 33325  
Telephone 954-835-1500  
Email: rmadaris@bioheartinc.com

**For Immediate Release**

## **Bioheart Expands Center of Excellence Program**

---

Sunrise, FL – March 19<sup>th</sup>, 2013 - Bioheart Inc. (BHRT.QB) announced today that it has expanded its Center of Excellence program to include a clinical site in Jamaica with the American Stem Cell and Anti-Aging Center. This site is in addition to the existing centers in Turkey, the Czech Republic and Mexico. American Stem Cell and Anti-Aging Center provides therapies for a variety of degenerative diseases at a fully equipped state-of-the-art private specialties hospital.

The center in Jamaica will now offer Bioheart's LipiCell™ product (fat derived stem cells). Adipose (fat) tissue is a plentiful source of stem cells and current applications for degenerative diseases are promising. Studies have shown that adipose derived cells may help reduce inflammation and promote the growth of new blood vessels. Because of the natural anti-inflammatory and immunomodulatory effects of the cells, they can help to promote healing in various conditions.

Bioheart's president and CEO, Mike Tomas said, "We are excited to begin offering the LipiCell product at another location. We have seen many positive results at

-MORE-

our other Centers of Excellence and we look forward to expanding indications and applications.”

### **About Bioheart, Inc.**

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart’s goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit [www.bioheartinc.com](http://www.bioheartinc.com), or visit us on Facebook: Bioheart and Twitter @BioheartInc.

###

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2011, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.